Evolving perspectives in contralateral breast cancer

European Journal of Cancer

Volumn 34, Issue 13, 1998, Pages 2000-2009

  Dawson, L A ^a   Chow, E ^a   Goss, P E ^a  

^a NONE

Author keywords

Chemoprevention; Contralateral breast cancer; Hereditary; Prophylactic mastectomy; Surveillance

Indexed keywords

BRCA1 PROTEIN; PREDNISONE; TAMOXIFEN;

BREAST BIOPSY; BREAST CANCER; BREAST EXAMINATION; CANCER INCIDENCE; CANCER SCREENING; CARCINOMA IN SITU; CLINICAL TRIAL; DISEASE PREDISPOSITION; FAMILIAL CANCER; GERM LINE; HUMAN; MAMMOGRAPHY; MASTECTOMY; META ANALYSIS; METASTASIS; MULTIPLE CANCER; OVARIECTOMY; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK FACTOR;

BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; HUMANS; MAMMOGRAPHY; MASTECTOMY; MUTATION; NEOPLASM PROTEINS; NEOPLASMS, MULTIPLE PRIMARY; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0032402237     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00208-1     Document Type: Review

References (128)

1. 1. National Cancer Institute of Canada. Canadian Cancer Statistics 1996, Toronto, Canada, 1996.
2. 2. Hankey BF, Curtis RE, Naughton MD, Boice Jr JD, Flannery JT. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J Natl Cancer Inst 1983, 70, 797-804.
3. 3. Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Sur 1984, 71, 711-714.
4. 4. Adami H-O, Bergstron R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population based case-control study. Cancer 1985, 55, 643-647.
5. 5. Robbins GF, Berg JW. Bilateral primary breast cancers. A prospective clinicopathologic study. Cancer 1964, 17(12), 1501-1527.
6. 6. Storm HH, Jensen OM. Risk of contralateral breast cancer in Denmark 1943-1980. Br J Cancer 1986, 54, 483-492.
7. 7. Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 1993, 11(8), 1545-1552.
8. 8. Adami HO, Malker B, Holmberg L, et al. The relationship between survival and age of diagnosis in breast cancer. N Engl J Med 1986, 315, 559-563.
9. 0) patients with 20 year followup. Surgery 1989, 106, 904-910.
10. 10. Fracchia AA, Borgen PI. Bilateral breast cancer. Sem Surg Oncol 1991, 7, 300-305.
11. 11. Roubidoux MA, Helvie MA, Lai NE. Paramagul C. Bilateral breast cancer: early detection with mammography. Radiology 1995, 196(2), 427-431.
12. 12. Burns PE, Dabbs K, May C, et al. Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Can Med Assoc J 1984, 130, 881-886.
13. 13. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985, 68, 99-112.
14. 14. Broet P, Rochefordiere A de la, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 1995, 13(7), 1578-1583.
15. 15. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14(10), 2738-2746.
16. 16. Del Turco MR, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V, for the National Research Council Project on Breast Cancer Follow-up. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. J Am Med Assoc. 1994, 271, 1593-1597.
17. 17. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial. J Am Med Assoc 1994, 271 (20), 1587-1592.
18. 18. Israeli D, Tartter PI, Brower ST, Mizrachy B, Bratton J. The significance of family history for patients with carcinoma of the breast. J Am Coll Surg 1994, 179, 29-32.
19. 19. Prior P, Waterhouse JAH. Incidence of bilateral tumours in a population-based series of breast cancer patients. I. Two approaches to an epidemiological analysis. Br J Cancer 1978, 37, 620-634.
20. 20. Bernstein JL, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 1992, 136, 925-936.
21. 21. Fracchi AA, Robinson D, Legaspi A, et al. Survival in bilateral breast cancer. Cancer 1985, 55, 1414-1421.
22. 22. Robinson E, Rennert G, Rennert HS, Neugut A. Survival of first and second primary breast cancer. Cancer 1993, 71, 172-176.
23. 23. Rochefordiere A de la, Asselain B, Scholl S, et al. Simultaneous bilateral breast carcinomas: A retrospective review of 149 cases. Int J Radiat Oncol 1994, 30(1), 35-41.
24. 24. Hislop TG, Elwood JM, Coldman AJ, et al. Second primary cancers of the breast; incidence and risk factors. Br J Cancer 1984, 49, 79-85.
25. 25. McCredie JA, Inch WR, Alderson M. Consecutive primary carcinoma of the breast. Cancer 1975, 35, 1472-1477.
26. 26. Smith BL, Bertagnolli M, Klein BB. Evaluation of the contralateral breast. Ann Surg 1992, 216(1), 17-21.
27. 27. Urban JA, Papachristou D, Taylor J. Bilateral breast cancer. Biopsy of the opposite breast. Cancer 1977, 40, 1968-1973.
28. 28. Wanebo W, Senofsky GM, Fechner RE, et al. Bilateral breast cancer: risk reduction by contralateral biopsy. Ann Surg 1985, 201, 667-677.
29. 29. Pressman PI. Selective biopsy of the opposite breast. Cancer 1986, 57, 577-580.
30. 30. Pressman PI. Bilateral breast cancer: the contralateral biopsy. Breast 1980, 5, 29-33.
31. 31. Leis HP Jr. Bilateral breast cancer: symposium on breast cancer. Surg Clin North Am 1978, 58, 833-841.
32. 32. Leis HP Jr. Managing the remaining breast. Cancer 1980, 46, 1026-1030.
33. 33. Fenig J, Arlen M, Livingstone SF, et al. The potential for carcinoma existing synchronously on a microscopic level within the second breast. Surg Gynecol Obstet 1975, 131, 394-396.
34. 34. King RE, Terz JJ, Lawrence W Jr. Experience with opposite breast biopsy in patients with operable breast cancer. Cancer 1976, 37, 43-45.
35. 35. Hoffman E. The contralateral breast biopsy in ipsilateral carcinoma. Southern Med J 1990, 83(9), 1009-1015.
36. 36. Lee JSY, Grant CS, Donohue JH, Crotty TB, Harmsen WS, Ilstrup DM. Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 1995, 118, 640-648.
37. 37. Staren ED, Robinson DA, Wit TR, Economou SG. Synchronous, bilateral mastectomy. J Surg Oncol 1995, 59, 75-79.
38. 38. Ringberg A, Palmer B, Linell F, Rychterova V, Ljungberg O. Bilateral and multifocal breast carcinoma. Eur J Surg Oncol 1991, 17, 20-29.
39. 39. Pennisi VR, Capozzi A, Perez FM. Subcutaneous mastectomy data: an interim report. Breast 1979, 5, 18-22.
40. 40. Barton FE Jr. Breast cancer, subcutaneous mastectomy, breast reconstruction. Selected Readings in Plastic Surgery 1986, 3, 1-23.
41. 41. Nielsen M, Christensen L, Anderson J. Contralateral cancerous breast lesions in women with clinically invasive breast carcinoma. Cancer 1986, 57, 897-903.
42. 42. Lawson R. Mammary cancer: the other breast. Can Med Assoc J 1955, 73, 676-677.
43. 43. Fisher ER, Fisher B, Sass R, Wickerham L and collaborating NSABP investigators. Pathological findings from the National Surgical Adjuvant Breast Project (Protocol.No. 4): XI. Bilateral breast cancer. Cancer 1984, 54, 3002-3011.
44. 44. Gustafsson A, Tartter PI, Browner ST, Lesnick G. Prognosis of patients with bilateral carcinoma of the breast. J Am Coll Surg 1994, 178, 111-116.
45. 45. Clark RM, Wilkinson RH, Mahony LJ, et al. Breast cancer: a 21 year experience with conservation surgery and radiation. Int J Radiat Oncol Bid Phyc 1982, 8, 967-975.
46. 46. Kurtz JM, Amalric R, Brandone H, Ayme Y, Spitalier J-M. Contralateral breast cancer and other second malignancies in patients treated by breast conserving therapy with radiation. Int J Radiat Oncol Biol Phys 1988, 15, 277-284.
47. 47. Brenner H, Engelsmann B, Stegmaier C, Ziegler H. Clinical epidemiology of bilateral breast cancer. Cancer 1993, 72, 3629-3635.
48. 48. Berte E, Buzdar AU, Smith TL, Hortobagyi GN. Bilateral primary breast cancer in patients treated with adjuvant therapy. Am J Clin Oncol 1988, 11, 114-118.
49. 49. Bailey MJ, Royce C, Sloane JP, et al. Bilateral carcinoma of the breast. Br J Surg 1980, 67, 514-516.
50. 50. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 1993, 52, 678-701.
51. 51. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE and the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994, 343, 692-695.
52. 52. Bernstein JL, Thompson WD, Risch N, Holford TR. The genetic epidemiology of second primary breast cancer. Am J Epidermal 1992, 136(8), 937-948.
53. 53. Anderson DE, Badzioch MD. Bilaterality in familial breast cancer patients. Cancer 1985, 56, 2092-2098.
54. 54. Horn PL, Thompson WD. Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol 1988, 128(2), 309-323.
55. 55. Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992, 326(12), 781-785.
56. 56. Lesser ML, Rosen PP, Kinne DW. Multicentricity and bilaterality in invasive breast carcinoma. Surgery 1982,91 (2), 234-240.
57. 57. Horn PL, Thompson WD. Risk of contralateral breast cancer. Associations with histologic, clinical and therapeutic factors. Cancer 1988, 62(2), 412-424.
58. 58. Horn PL, Thompson WD. Risk of contralateral breast cancer: associations with factor related to initial breast cancer. Am J Epidemiol 1988, 128(2), 309-323.
59. 59. Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S. Incidence of female breast cancer among atomic bomb survivors. Radiat Res 1994, 138, 209-223.
60. 60. Yahalom J, Petrek JA, Biddinger PW, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 1992, 10, 1674-1681.
61. 61. Weber BL. Susceptibility genes for breast cancer. N Engl J Med 1994, 331(22), 1523-1524.
62. 62. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. Survival and tumour characteristics of breast cancer patients germline mutations of BRCA1. Lancet 1998, 351, 316-321.
63. 63. Porter DE. Breast cancer survival in BRCA1 carriers. Lancet 1993, 341, 184-185.
64. 64. Williard W, Morain WB, Baughman RD, et al. A further indication for prophylactic mastectomy. Surgery 1986, 99, 82-86.
65. 65. Swift M, Morrell D, Massey RB, et al. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1988, 325, 244-245.
66. 66. Cortessis V, Ingles S, Millikan R, et al. Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer. Cancer Res 1993, 53(21), 5083-5086.
67. 67. Wooster R, Ford D, Mangion J, et al. Absence of linkage to the ataxia-telangiectasia locus in familial breast cancer. Human Genet 1993, 92, 91-94.
68. 68. Land CE. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. J Am Med Assoc 1995, 274, 402-407.
69. 69. Baral E, Larsson L-E, Mattsson B. Breast cancer following irradiation of the breast. Cancer 1977, 40, 2905-2910.
70. 70. Hoffman DA, Lonstein JE, Morin MM, et al. Breast cancer in women with scoliosis exposed to multiple diagnostic X-rays. J Natl Cancer Inst 1989, 81, 1307-1312.
71. 71. Shore RE, Hildreth N, Woodard E, Dvoretsky P, Hempelmann L, Pasternack B. Breast cancer among women given X-ray therapy for acute postpartum mastitis. J Natl Cancer Inst 1986, 77, 689-696.
72. 72. Cook KL, Adler DD, Lichter AS, Lichter AS, Ikeda DM, Helvie MA. Breast carcinoma in young women previously treated for Hodgkin disease. Am J Roentgenol 1990, 155, 39-42.
73. 73. Janjan NA, Wilson JF, Gillin M, et al. Mammary carcinoma developing after radiotherapy and chemotherapy for Hodgkin's disease. Cancer 1988, 61, 252-254.
74. 74. Li FP, Corkery J, Canellos G, Neitlich HW. Breast cancer after Hodgkin's disease in two sisters. Cancer 1981, 47, 200-202.
75. 75. Colvett KT. Bilateral breast carcinoma after radiation therapy for Hodgkin's disease. Southern Med J 1995, 88(2), 239-242.
76. 76. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993, 85, 25-31.
77. 77. Anderson N, Lokich J. Bilateral breast cancer after cured Hodgkin's disease. Cancer 1990, 65, 221-223.
78. 78. Amalric R, Spitalier JM. Radiation as the sole method of treatment in carcinoma of the breast. In Zuppinger A, Hellriegel W, eds. Handbuch der medizinischen Radiologie, Band XIX, Heidelberg, Springer, 1982, 301-346.
79. 79. Land CE. Low dose irradiation. A cause of breast cancer? Cancer 1980, 46, 868-873.
80. 80. Souba WW, McKenna RJ Jr, Benjamin H, Raymond AK, Mountain CF. Radiation-induced sarcomas of the chest wall. Cancer 1986, 57, 610-615.
81. 81. Spitalier JM, Gambarelli J, Brandone H, et al. Breast-conserving surgery with radiation therapy for operable mammary carcinoma: A 25 year experience. World J Surg 1986, 10, 1014-1020.
82. 82. Shore RE, Hemplemann LH, Kowaluk E, et al. Breast neoplasms in women treated with x-rays for acute postpartum mastitis. J Natl Cancer Inst 1977, 59, 813-822.
83. 83. Schell SR, Montague ED, Spanos WJ Jr, et al. Bilateral breast cancer in patients with initial stage I and II disease. Cancer 1982, 50, 1191-1194.
84. 84. Storm HH, Anderson M, Boice JD, et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst 1992, 84, 1245-1250.
85. 85. Mariani L, Coradini D, Biganzoli E, et al. Prognostic factors for metachronous contralateral breast cancer: a comparison of the linear Cox regression model and its artificial neural network extension. Breast Cancer Res Treat 1997, 44(2), 167-178.
86. 86. Gogas J, Markopoulos C, Skandalakis P, Gogas H. Bilateral breast cancer. Am Syrg 1993, 59(11), 733-735.
87. 87. Brankovic-Magic M, Nikolic-Vukosavljevic D, Kanjer K, et al. Estrogen and progesterone receptor content in bilateral breast cancer. Pathol Res Practice 1995, 191, 16-24.
88. 88. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996, 14(1), 103-110.
89. 89. Veronesi U, De Palo G, Costa A, Formelli F, Decensi A. Chemoprevention of breast cancer with fenretinide. IARC Scientific Publications 136 Lyon International Agency for Research on Cancer, 1996, 87-94.
90. 90. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992, 339, 1-15, 71-85.
91. 91. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320(8), 479-484.
92. 92. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 1991, 83, 1278-1280.
93. 93. Love RR. The National Surgical Adjuvant Breast Project (NSABP) Breast Cancer Prevention Trial Revisted. Cancer Epidemiol Biomarkers Prev 1993, 2, 403-407.
94. 94. Stewart HJ for The Scottish Cancer Trials Breast Group. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst Monogr 1992, 11, 117-120.
95. 95. Rutquvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991, 83, 1299-1306.
96. 96. Baum M, Hough J, Riley D. Results of the Cancer Research Campaign adjuvant trial for preoperative cyclophosphamide and long-term tamoxifen in early breast cancer reported in the tenth year of follow-up. Acta Oncol 1992, 31, 251-257.
97. 97. Lavey RS, Eby NL, Prosnitz LR. Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer. Cancer 1990, 66, 874-881.
98. 98. Herring MK, Buzdar AU, Smith TL, Hortobagyi GN, Blumenschein GR. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol 1986, 9(3), 269-275.
99. 99. Hirayama T, Wynder E. Study of epidemiology of cancer of the breast: influence of hysterectomy. Cancer 1962, 15, 28-38.
100. 100. MacMahon B, Feinieb M. Breast cancer in relation to nursing and menopausal history. J Natl Can Inst 1960, 24, 733-753.
101. 101. Meakin JW, Hayward JL, Panzarella T, et al. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 1996, 37, 11-19.
102. 102. Humphrey LJ. Subcutaneous mastectomy is not a prophylaxis against carcinoma of the breast; opinion or knowledge? Am J Surg 1983, 145, 311-312.
103. 103. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis-Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997, 336, 1465-1471.
104. 104. American Society of Clinical Oncology. Recommended breast cancer surveillance guidelines. J Clin Oncol 1997, 15, 2149-2156.
105. 105. Kurebayashi J, Shimozuma K, Sonoo H. The practice of breast self examination in the earlier detection and better clinical course of Japanese women with breast cancer. Surg Today 1994, 24(4), 337-341.
106. 106. Grady KE. The efficacy of breast self-examination. J Gerontol 1992, 47, 69-74.
107. 107. Ellman R, Moss SM, Coleman D, et al. Breast self-examination programmes in the trial of early detection of breast cancer. Br J Cancer 1993, 68, 208-212.
108. 108. Auvinen A, Elovainio L, Hakama M. Breast self-examination and survival from breast cancer: a prospective follow-up study. Breast Cancer Res Treat 1996, 38, 161-168.
109. 109. Senofsky GM, Wanebo HJ, Wilhelm MC, et al. Has monitoring of the contralateral breast improved prognosis in patients treated for primary breast cancer? Cancer 1986, 57, 597-602.
110. 110. Ciatto S, Ambrogetti D, Bonardi R, Bravetti P, Del Tureo MR. Prognostic impact of early detection of contralateral primary breast cancer. Tumori 1990, 76, 370-373.
111. 111. Mellink WAM, Holland R, Hendricks JHCL, Peeters PHM, Rutgers EJT, Daal WAJ van. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer 1991, 67, 1844-1848.
112. 112. Shapiro S, Venet W, Strax P, et al. Ten to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982, 69, 349-355.
113. 113. Shapiro S. Screening assessment of current studies. Cancer 1994, 74, 231-238.
114. 114. Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare Lancet 1985, 1, 829-832.
115. 115. Morrison AS, Brisson J, Khalid N. Breast cancer incidence and mortality in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 1988, 80, 1540-1547.
116. 116. Peer PGM, Werre JM, Mravunac M, Hendriks JHCL. Effect on breast cancer mortality of biennial mammographic screening of women under age 50. Int J Cancer 1995, 60, 808-811.
117. 117. Eskelinen M, Kataja V, Hamalainen E, Kosma V-M, Penttila I, Alhava E. Serum tumour markers CEA, AFP, CA 15-3, TPS and neu in diagnosis of breast cancer. Anticancer Res 1997, 17, 1231-1234.
118. 118. Beck JR. Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med 1986, 110, 685-686.
119. 119. Vizcarra E, Lluch A, Cibrian R, et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of first metastasis. Breast Cancer Res Treat 1996, 37(3), 209-216.
120. 120. American Society of Clinical Oncology. 1997 update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer. J Clin Oncol 1998, 16(2), 793-795.
121. 121. Locker GJ, Mader RM, Braun J, et al. New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer. Oncology 1995, 52(2), 140-144.
122. 122. Engel K, Schmid H, Hanke J, et al. CA 15.3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer. Geburtshilfe und Frauenheilkunde 1998, 48(5), 309-312.
123. 123. Bombardieri E, Pizzichetta M, Veronesi P, et al. CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 1992, 29A(1), 144-146.
124. 124. Abe O, Nomura Y, Izuo M, et al. Response to rechallenged tamoxifen of metastatic breast cancer relapsed after surgical adjuvant tamoxifen. Japan J Cancer Chemother 1991, 18, 1333-1336.
125. 125. Muss HB, Smith LR, Cooper MR. Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J Clin Oncol 1987, 5(10), 1556-1558.
126. 126. Watkins SM. The value of high dose tamoxifen in post-menopausal breast cancer patients progressing on standard doses: pilot study. Br J Cancer 1988, 57, 320-321.
127. 127. Muss HB. Endocrine therapy for advanced breast cancer, a review. Breast Cancer Res Treat 1992, 21, 15-26.
128. 128. International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996, 14, 1885-1894.